Cartilage Damage Articles & Analysis: Older
26 news found
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in Chicago, IL on Tuesday, March 22nd at 11:00 a.m. Central Time. A webcast of the presentation will be available on the Investor Relations section of the ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9th at 1:30 p.m. Eastern Time. A webcast of the presentation will be available on the Investor Relations section of ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts. The new facility, which will ...
” About Hyalex Orthopaedics Hyalex is a privately-held medical device company headquartered in Lexington, MA, developing transformational synthetic cartilage technology and implant systems for diseased and damaged joints. HYALEX® Cartilage is protected by more than 17 patents and trademarks worldwide. The HYALEX® ...
” Hyalex Orthopaedics is developing the HYALEX Cartilage System, which is intended to repair cartilage lesions and restore function for patients with loss of knee articular cartilage and bone requiring surgery. ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 7:30 a.m. Eastern Time. A webcast of the presentation will be available on the Investor Relations section of the Vericel ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on Thursday November 18th, at 10:00a.m. Eastern Time. A webcast of the presentation will be available on the Investor ...
It inhibits the breakdown of homogentisic acid in the body, which can cause significant damage to the bones, cartilage and tissues of those affected. Commenting on the campaign, Nick Sireau, CEO and Chairman of the Board of Trustees at the AKU Society, says: “We’re delighted that Healx is supporting our work to build the world’s first registry ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13, 2021, at 4:15p.m. Eastern Time. A webcast of the presentation will be available on the ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of Patrick J. Fowler as Senior Vice President, Corporate Development and Strategy, effective today. Mr. Fowler joins Vericel with over 15 years of business development, strategy and commercial operations experience in the biotech and medical technology ...
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Ladenburg Thalmann Healthcare Conference. The conference is being conducted in a virtual format and the presentation will take place on Tuesday, July 13, 2021, at 9:00 a.m. ...
Food and Drug Administration (FDA). The HYALEX Cartilage System is intended to repair cartilage defects and restore function for patients with loss of knee articular cartilage and bone requiring surgery. ...
Osteochondral lesions are a tear or fracture that involves damage to both the cartilage and underlying bone. Osteochondral defects often occur in joints and are most common in the articular cartilage and subchondral bone structures of the knee and ankle. Articular cartilage injuries often occur following an acute traumatic injury ...
The aim of their research was developing a way to effectively restore damaged cartilage that leads to osteoarthritis in the hip, knee and other joints in the body. ...
Applications HD 3D imaging technology used in the Vimago system provides a solid volume of data, resulting in gapless, non-interpolated imaging data, delivering a 3D map of densities with spatial resolution that is the same in all three dimensions. Hard Tissue Applications: Skulls - sinus, nasal, bulla, ears, brain, oncology, trauma Orthopedics - stifles, elbows, hips, carpus/tarsus, ...
Verve Medical Products is one of Canada’s leading medical device distributors, and we are looking forward to working with their team to provide Canadian orthopaedic surgeons with a proven option for the treatment of articular cartilage defects.” BioPoly implants have been used in knee surgeries throughout Europe since 2012. The fact that BioPoly partial resurfacing ...
Rather than replacing the entire joint, the novel BioPoly® resurfacing implants are designed to replace only the damaged cartilage of a patient’s joint. The BioPoly® material used in the implants is a proprietary combination of hyaluronic acid and ultra-high molecular weight polyethylene, creating a self-lubricating polymer with enhanced wear ...
KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a License and Supply Agreement with TRB Chemedica, a leading pharmaceutical and biotechnology company. KiOmed Pharma announces the granting of the CE mark for its first implantable product intended to treat osteoarthritis symptoms and the signing of a ...
Utilizing simple, reproducible minimally invasive surgical techniques, the novel BioPoly® resurfacing implants are designed to replace only the damaged cartilage of a patient’s joint rather than to replace the entire joint. ...
The material behaves like a synthetic cartilage, allowing the implants to replace the damaged cartilage of a patient’s joint rather than the entire joint. ...